Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

Citation: Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M.: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther, Volume 320 (1), 2007
Authors: Fujikura H, Fujimori Y, Hiratochi M, Isaji M., Itoh F, Katsuno K, Komatsu Y, Takemura Y
Journal: J Pharmacol Exp Ther
Year: 2007
DOI: 10.1124/jpet.106.110296
PubMed: 17050778
Machine-readable: REST API RDF

Publication